Fundz
Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Prytime Medical Names Rich Wojcik As Chief Financial Officer

PRIVATEApr 30, 2024about 2 years ago

Position

Chief Financial Officer

Company

Prytime Medical Devices

Rich Wojcik
United States

Description

Prytime Medical Devices Inc. is excited to announce the appointment of Rich Wojcik as the Chief Financial Officer. Rich Wojcik, recently named a Top 25 CFO of San Antonio by Top CFOs, brings a wealth of finance experience and a strong strategic planning background, making him the ideal CFO at this stage of the company's development

Company Information

Company

Prytime Medical Devices

Location

United States

About

Prytime Medical Devices, Inc., an innovative medical device company, designs, develops and commercializes minimally invasive solutions for hemorrhage control. The company’s flagship product is the ER-REBOA™ Catheter, a 7 Fr compatible balloon catheter designed specifically for rapid, temporary occlusion of large vessels in the emergency and critical care environment during the REBOA (Resuscitative Endovascular Occlusion of the Aorta) procedure. The underlying intellectual property for the ER-REBOA™ Catheter was conceived by experienced military vascular and trauma surgeons, COL. Todd Rasmussen and Dr. Jonathan Eliason, based on lessons learned on the battlefront during combat. The first guidewire free prototype was developed and tested on animals in 2011. Shortly thereafter the company was founded. In October 2015 the ER-REBOA™ Catheter received 510(K) clearance and we began commercializing the device the US market in 2016, followed by the European market. Now approved in Canada as well, use of the device is increasing worldwide, with the total number of hospitals using the ER-REBOA™ Catheter now exceeding 250. The initial market for the device is trauma, with a strong pull developing in adjacent markets including cardiac arrest, postpartum hemorrhage, interventional radiology, perisurgical and pre-hospital in the US and abroad. At Prytime, we are proud to be a part of bringing military medical innovation to the civilian marketplace. We believe that no one should bleed to death; and the sooner you stop bleeding, the better.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Prytime Medical Devices's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.